2015 Biotech Stock Preview: Rhythms Of The 'PermaBull'
- Biotech stocks should outperform the market in 2015. However the biotech sector is linked to healthcare fundamentals like government pricing policy.
- The industry is better financed than any time in its history driving innovation and new product growth. The appetite for M&A and IPOs will continue.
- Biopharmaceutical stocks defy traditional analysis and have been a safe haven from global economic news.
Biotech Stocks Get Turbo Boost From Idenix Deal
- M&A theme is back for small and mid caps.
- Rally re-traces Q1 correction up to mid-point.
- Bullish sentiment enables traders.
Biotech Rout Not Surprising: Surveying The Damage
- Biotech stocks decoupled from fundamentals and ran on exuberance.
- Bull Market is Intact but intermediate bottom not confirmed.
- Top Ten Reasons For Sell-Off and too early to call next steps.
Large-Cap Biopharmaceuticals Are Core Holdings After Sell-Off: AbbVie, Amgen, Gilead
- Bull market in biotech is intact with more clarity.
- Momentum stocks should be avoided - appetite for speculation is diminished.
- Biotech stocks are still holding near February lows - large-cap review and picks.
- Biotech Bull Market Up 6%+ YTD: Key Trends To Watch Update #2
- Biotech Bull Market Key Trend No. 1: 5 Large Cap Biopharmas Plus 2
- Biotech Bull Market: 2014 Key Trends To Watch
- NanoString Technologies: An Emerging Growth Play In Molecular Diagnostics
- 'Long Only' Funds? Shorting Stocks Is So 2008
- Valuation Models For Biopharmaceutical Stocks
- Are Biotech M&A Premiums Already Built In? Valuations Do Matter
- Emerging Biomarker Companies Redux: Positioned For Growth
- Biotech Stocks Get A Turbo Boost From Vertex
- Is There No End To The Biotech Bull Market?
- Biopharmaceutical Sector Attempts Another Move To New Highs
- Biotech Bull Market: Are ETFs Better Than Mutual Funds?
- Update On Emerging Biomarker Diagnostics: BG Medicine, Response Genetics, Vermillion
- Who Knows About The Bull Market In Biotech Stocks?
- Biotech Sector Avoids Nasty Correction And Hits New Highs
- Consolidation Continues In Mid Cap DX Companies: Bull Market In Biotech Hits New Highs
- Emerging Biomarker Diagnostics: BGMedicine And Vermillion
- Biotech Bull Market Intact: Rayno Biopharmaceutical Portfolio Outperforms
- Response Genetics Stock Soars 31% On $7.8M Offering News
- Technology Convergence Trends in the Biopharma Sector: Abbott, Alere and Merge
- Life Science Portfolios: Reflecting on a Year of Out-Performance
- Explore the Many Flavors of Healthcare Stocks: Biotech, Drugs, Life Sciences, MedTech
- Balance Your Portfolio With Three Stable Biotech ETFs
- Novel Diagnostic Tests Utilizing Biomarkers Working Well for Vermillion
- Cardiovascular Systems Gains Traction
- Immucor Cuts Guidance on Lower Demand
- Successful IPOs in Genomics Could Ignite Biotech Stocks
- AACC Meeting Buzz Fuels Rally in Diagnostics